BIAF (bioAffinity Technologies) Earnings per share growth rate in current year

Official company branding of bioaffinitytech.com (BIAF)

Slow physician adoption of tests and marketing expenses previously constrained revenues for bioAffinity Technologies (BIAF). The volatility of annual earnings per share on the GURU.Markets chart currently reflects the present trend, where 0.00 indicates the level of this metric. Ahead lies the B2B expansion of the non-invasive CyPath Lung method, although patent disputes with tech startups will remain a key challenge.

BIAF (bioAffinity Technologies Inc.) Earnings growth in current year history from 04/28/2023 to 11/11/2026

Analytical breakdowns and data insights for company bioaffinitytech.com (BIAF)

- price and consensus price forecast:
Stock Quotes bioAffinity Technologies, Inc.|BIAF - Analyst Consensus Forecast
- business market valuation indicators:
Market Value bioAffinity Technologies, Inc.|BIAF - Total Company Value
- balance sheet equity data:
Accounting Value of a Share bioAffinity Technologies|BIAF - Book Capitalization|Market Value to Book Value Ratio bioaffinitytech.com|BIAF - Company Total Assets
- debt and liquidity details:
Total Debt to Capital Coefficient bioAffinity Technologies|BIAF - Long-Term Debt to Equity|Current Liabilities to Capital bioAffinity Technologies, Inc.|BIAF - Company Aggregate Debts|Debts to Book Capitalization bioAffinity Technologies, Inc.|BIAF - Company Long-Term Debts|Current Liabilities bioAffinity Technologies|Critical Liquidity Ratio bioaffinitytech.com
- net income and valuation multiples indicators:
BIAF - Net Profit|Company Profit Forecast bioAffinity Technologies|BIAF - Price to Earnings Ratio|Price to Future Earnings Ratio bioAffinity Technologies, Inc.|BIAF - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio bioAffinity Technologies, Inc.|BIAF - Operating profit before deduction of amortization|Earnings per share for the last four quarters bioAffinity Technologies|BIAF - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months bioaffinitytech.com|BIAF - Net earnings per share growth this year|Expected earnings per share trend next year bioAffinity Technologies
Fundamental valuation:bioAffinity Technologies
Mass-produced product of bioAffinity Technologies

This metric measures the year-over-year dynamics of earnings per share, reflecting the efficiency of capital generation. For bioAffinity Technologies (BIAF), this growth depends directly on the commercialization of patented cancer tests and their recognition by insurance companies. Analyzing the year-over-year change in EPS allows investors to distinguish a speculative asset from a fundamentally sustainable business, confirming the actual strength of the economic moat.

Direct competitors

Net earnings per share growth this year ArriVent Corp|LTRN (Lantern Pharma Inc) - Earnings growth in current year|Earnings per share growth rate in current year eEFFECTOR EFTR